Demetra Holding has formed with investment from Tecres and Keensight, which acquired aap Implantate’s biomaterials assets. Tecres and aap Biomaterials will proceed as separate entities with discrete business strategies.
Tecres, a specialist in bone substitutes and bone cements, has also developed the antibiotic Spacer® line to treat post-op infections in hip, knee and shoulder.
The combined businesses will benefit from industrial and R&D synergies, including biomaterials expertise. All present management teams and operations will remain in place.
Demetra employees will number ~140, operating in >70 countries.
Demetra Holding has formed with investment from Tecres and Keensight, which acquired aap Implantate's biomaterials assets. Tecres and aap Biomaterials will proceed as separate entities with discrete business strategies.
Tecres, a specialist in bone substitutes and bone cements, has also developed the antibiotic Spacer® line to treat post-op...
Demetra Holding has formed with investment from Tecres and Keensight, which acquired aap Implantate’s biomaterials assets. Tecres and aap Biomaterials will proceed as separate entities with discrete business strategies.
Tecres, a specialist in bone substitutes and bone cements, has also developed the antibiotic Spacer® line to treat post-op infections in hip, knee and shoulder.
The combined businesses will benefit from industrial and R&D synergies, including biomaterials expertise. All present management teams and operations will remain in place.
Demetra employees will number ~140, operating in >70 countries.
Copy to clipboard 
